Multiple Myeloma | Specialty

Landgren Lauds Promise of Carfilzomib Quadruplet Regimen in Newly Diagnosed Myeloma

June 16th 2021

C. Ola Landgren, MD, PhD, discusses important research efforts that led to the launch of the phase 2 MANHATTAN trial, the results achieved with the weekly carfilzomib quadruplet regimen in patients with newly diagnosed multiple myeloma, and the potential for this approach irrespective of transplant eligibility status.

Dr. Davies on Future Research Directions With Isatuximab in Multiple Myeloma

June 16th 2021

Faith Davies, MD, discusses future research directions with isatuximab in the treatment of patients with multiple myeloma.

Deep Responses Yielded With Daratumumab Plus CyBorD Followed by Daratumumab Maintenance in Multiple Myeloma

June 14th 2021

For patients with newly diagnosed or relapsed multiple myeloma, regardless of transplant status, daratumumab plus cyclophosphamide, bortezomib, and dexamethasone induction followed by daratumumab maintenance therapy achieved durable and deep responses.

Cilta-Cel Induces Deep, Durable Responses in Relapsed/Refractory Multiple Myeloma

June 13th 2021

Ciltacabtagene autoleucel continued to yield early, deep, and durable responses after longer follow-up in patients with relapsed/refractory multiple myeloma.

Early Intervention For Neurotoxicity Can Improve Outcomes With Cilta-Cel in Relapsed/Refractory Multiple Myeloma

June 13th 2021

Neurologic adverse effect associated with CAR T-cell therapies like ciltacabtagene autoleucel can be managed without long-term lasting effects, as long as they are caught and treated promptly in patients with relapsed/refractory multiple myeloma.

Daratumumab Plus Standard of Care Continues to Improve Survival in Newly Diagnosed Multiple Myeloma

June 12th 2021

The addition of daratumumab to lenalidomide and dexamethasone continued to reduced the risk of death by 32% compared with Rd alone in patients with newly diagnosed multiple myeloma who are transplant ineligible after almost 5 years of follow-up.

Daratumumab Maintenance Prolongs Responses Following ASCT and Standard Consolidation/Induction in Myeloma

June 12th 2021

Daratumumab maintenance therapy yielded an increase in response following autologous stem cell transplant plus induction and consolidation therapy with bortezomib, thalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma.

Intensified Daratumumab Plus CVRd and Bortezomib-Augmented ASCT Demonstrates Promise in Ultra High–Risk Multiple Myeloma

June 11th 2021

Intensified induction therapy with daratumumab in addition to cyclophosphamide, bortezomib, lenalidomide, and dexamethasone and bortezomib-augmented autologous stem cell transplant yielded robust responses in patients with ultra¬ high–risk multiple myeloma or primary plasma cell leukemia

Cilta-Cel Elicits Improved Outcomes in Relapsed/Refractory Myeloma Vs Conventional Therapy

June 11th 2021

Patients with relapsed/refractory multiple myeloma who were treated with ciltacabtagene autoleucel experienced improved outcomes over those who received a conventional therapy

Evolving Treatment Options for Relapsed/Refractory Multiple Myeloma

June 11th 2021

Drs Hoffman and Richter discuss a promising new treatment for patients with relapsed/refractory multiple myeloma who are not eligible for a clinical trial after 4 lines of therapy.